• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Prostate Cancer - Pipeline Review, H2 2012 Product Image

Prostate Cancer - Pipeline Review, H2 2012

  • ID: 2233850
  • August 2012
  • 498 pages
  • Global Markets Direct

Prostate Cancer – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Prostate Cancer - Pipeline Review, H2 2012', provides an overview of the Prostate Cancer therapeutic pipeline. This report provides information on the therapeutic development for Prostate Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Prostate Cancer. 'Prostate Cancer - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Prostate Cancer.
- A review of the Prostate Cancer products under development by companies and universities/research institutes based on READ MORE >

2
List of Tables 9
List of Figures 16
Introduction 17
REPORT COVERAGE 17
Prostate Cancer Overview 18
Therapeutics Development 19
An Overview of Pipeline Products for Prostate Cancer 19
Prostate Cancer Therapeutics under Development by Companies 21
Prostate Cancer Therapeutics under Investigation by Universities/Institutes 37
Late Stage Products 47
Comparative Analysis 47
Mid Clinical Stage Products 48
Comparative Analysis 48
Early Clinical Stage Products 49
Comparative Analysis 49
Discovery and Pre-Clinical Stage Products 50
Comparative Analysis 50
Prostate Cancer Therapeutics – Products under Development by Companies 51
Prostate Cancer Therapeutics – Products under Investigation by Universities/Institutes 71
Companies Involved in Prostate Cancer Therapeutics Development 93
Bristol-Myers Squibb Company 93
Johnson & Johnson 94
Boehringer Ingelheim GmbH 95
Celsion Corporation 96
Abbott Laboratories 97
Amgen Inc. 98
Sanofi-Aventis 99
Adherex Technologies Inc. 100
AstraZeneca PLC 101
Eli Lilly and Company 102
Viralytics Ltd. 103
GlaxoSmithKline plc 104
Bioniche Life Sciences, Inc. 105
Genentech, Inc. 106
Inovio Biomedical Corporation 107
Bavarian Nordic A/S 108
Isis Pharmaceuticals, Inc. 109
Merck & Co., Inc. 110
AbGenomics International, Inc. 111
Oxford BioMedica plc 112
Generex Biotechnology Corporation 113
Takeda Pharmaceutical Company Limited 114
Plexxikon Inc. 115
Light Sciences Oncology, Inc. 116
Amorfix Life Sciences Ltd. 117
Ipsen S.A. 118
Panacea Pharmaceuticals, Inc. 119
Bio-Path Holdings, Inc. 120
BioSante Pharmaceuticals, Inc. 121
ZIOPHARM Oncology, Inc. 122
Millennium Pharmaceuticals, Inc. 123
Novartis AG 124
Aphios Corporation 125
Astellas Pharma Inc. 126
BioMarin Pharmaceutical Inc. 127
Cephalon, Inc. 128
Genta Incorporated 129
GTx, Inc. 130
Nippon Shinyaku Co., Ltd. 131
Orion Corporation 132
Pfizer Inc. 133
Teva Pharmaceutical Industries Limited 134
Progenics Pharmaceuticals, Inc. 135
Santaris Pharma A/S 136
Exelixis, Inc. 137
Aduro BioTech 138
Menarini Group 139
Alfacell Corporation 140
Celgene Corporation 141
Bayer AG 142
MannKind Corporation 143
Merck KGaA 144
Advaxis, Inc. 145
Alchemia Limited 146
Addex Pharmaceuticals 147
Genesis Research and Development Corporation Ltd. 148
GW Pharmaceuticals plc 149
Hollis-Eden Pharmaceuticals, Inc. 150
Celldex Therapeutics, Inc. 151
Anavex Life Sciences Corp. 152
Cougar Biotechnology, Inc. 153
ValiRx Plc 154
Active Biotech AB 155
AEterna Zentaris Inc. 156
Antisense Therapeutics Limited 157
Bionomics Limited 158
Molecular Insight Pharmaceuticals, Inc. 159
Northwest Biotherapeutics, Inc. 160
Novelos Therapeutics, Inc. 161
Nymox Pharmaceutical Corporation 162
Cleveland BioLabs, Inc. 163
Oncolytics Biotech Inc. 164
Oncothyreon Inc 165
Compugen Ltd. 166
Osta Biotechnologies Inc. 167
Peregrine Pharmaceuticals, Inc. 168
Medivation, Inc. 169
La Jolla Pharmaceutical Company 170
Jazz Pharmaceuticals, Inc. 171
ADVENTRX Pharmaceuticals 172
Telik, Inc. 173
Soligenix, Inc. 174
Poniard Pharmaceuticals, Inc. 175
Regeneron Pharmaceuticals, Inc. 176
Champions Biotechnology, Inc. 177
Oncogenex Pharmaceuticals, Inc. 178
ProMetic Life Sciences Inc. 179
Progen Pharmaceuticals Limited 180
Green Cross Corporation 181
Innocell Corporation 182
Quest PharmaTech Inc. 183
Samaritan Pharmaceuticals, Inc. 184
Threshold Pharmaceuticals, Inc. 185
Synta Pharmaceuticals Corp. 186
Sareum Holdings plc 187
Oasmia Pharmaceutical AB 188
e-Therapeutics plc 189
RXi Pharmaceuticals Corporation 190
Hybrigenics S.A. 191
Rexahn Pharmaceuticals, Inc. 192
Merrion Pharmaceuticals Plc 193
Emiliem, Inc. 194
Oryzon 195
Angelini Group 196
Debiopharm Group 197
Antisense Pharma GmbH 198
Colby Pharmaceutical Company 199
Avanti Therapeutics 200
Camurus AB 201
Immupharma Plc 202
Phosphagenics Limited 203
ImQuest Life Sciences 283
CytoVac A/S 284
Prostate Cancer – Therapeutics Assessment 285
Assessment by Monotherapy Products 285
Assessment by Combination Products 286
Assessment by Route of Administration 287
Assessment by Molecule Type 289
Drug Profiles 292
Yervoy - Drug Profile 292
degarelix acetate - Drug Profile 294
TV-1011 - Drug Profile 295
Zytiga - Drug Profile 297
TASQ - Drug Profile 299
Enzalutamide - Drug Profile 301
Cabozantinib - Drug Profile 305
Leuprolide 22.5 - Drug Profile 307
Leuprolide 7.5 - Drug Profile 309
DCVax-Prostate - Drug Profile 310
degarelix acetate one month formulation - Drug Profile 311
degarelix acetate one month formulation - Drug Profile 312
SR Leuprolide - Drug Profile 313
Alpharadin - Drug Profile 314
Docetaxel + Prednisone + Atrasentan - Drug Profile 316
Antiandrogen Therapy + LHRH agonist - Drug Profile 318
Androgen Blockade Therapy + Zoledronic Acid - Drug Profile 320
Gemcitabine + Cisplatin + Bevacizumab - Drug Profile 321
Bicalutamide + Goserelin + Radiation Therapy - Drug Profile 322
Radiation Therapy + Bicalutamide - Drug Profile 323
Radiation Therapy + Androgen Deprivation Therapy - Drug Profile 325
Radiation Therapy + Leuprolide Acetate - Drug Profile 327
Hormone Therapy + Docetaxel + Estramustine - Drug Profile 329
Hormone Therapy - Drug Profile 332
Dutasteride - Drug Profile 392
Flutamide + Goserelin Acetate + Low-LET Photon Therapy - Drug Profile 393
Gemcitabine + Cisplatin - Drug Profile 395
Zaltrap - Drug Profile 397
Docetaxel - Drug Profile 399
ProstAtak - Drug Profile 400
Docetaxel + Estramustine - Drug Profile 402
CB7630 + Prednisone - Drug Profile 403
Prostate Cancer Therapeutics – Drug Profile Updates 405
Prostate Cancer Therapeutics – Discontinued Products 440
Prostate Cancer Therapeutics - Dormant Products 449
Prostate Cancer – Product Development Milestones 485
Featured News & Press Releases 485
Appendix 492
Methodology 492
Coverage 492
Secondary Research 492
Primary Research 492
Expert Panel Validation 492
Contact Us 493
Disclaimer 493

List of Tables
Number of Products Under Development for Prostate Cancer, H2 2012 24
Products under Development for Prostate Cancer – Comparative Analysis, H2 2012 25
Number of Products under Development by Companies, H2 2012 27
Number of Products under Development by Companies, H2 2012 (Contd..1) 28
Number of Products under Development by Companies, H2 2012 (Contd..2) 29
Number of Products under Development by Companies, H2 2012 (Contd..3) 30
Number of Products under Development by Companies, H2 2012 (Contd..4) 31
Number of Products under Development by Companies, H2 2012 (Contd..5) 32
Number of Products under Development by Companies, H2 2012 (Contd..6) 33
Number of Products under Development by Companies, H2 2012 (Contd..7) 34
Number of Products under Development by Companies, H2 2012 (Contd..8) 35
Number of Products under Development by Companies, H2 2012 (Contd..9) 36
Number of Products under Development by Companies, H2 2012 (Contd..10) 37
Number of Products under Development by Companies, H2 2012 (Contd..11) 38
Number of Products under Development by Companies, H2 2012 (Contd..12) 39
Number of Products under Development by Companies, H2 2012 (Contd..13) 40
Number of Products under Development by Companies, H2 2012 (Contd..14) 41
Number of Products under Investigation by Universities/Institutes, H2 2012 43
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 44
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 45
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..3) 46
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..4) 47
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..5) 48
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..6) 49
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..7) 50
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..8) 51
Comparative Analysis by Late Stage Development, H2 2012 52
Comparative Analysis by Mid Clinical Stage Development, H2 2012 53
Comparative Analysis by Early Clinical Stage Development, H2 2012 54
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 55
Products under Development by Companies, H2 2012 56
Products under Development by Companies, H2 2012 (Contd..1) 57
Products under Development by Companies, H2 2012 (Contd..2) 58
Products under Development by Companies, H2 2012 (Contd..3) 59
Products under Development by Companies, H2 2012 (Contd..4) 60
Products under Development by Companies, H2 2012 (Contd..5) 61
Products under Development by Companies, H2 2012 (Contd..6) 62
Products under Development by Companies, H2 2012 (Contd..7) 63
Products under Development by Companies, H2 2012 (Contd..8) 64
Products under Development by Companies, H2 2012 (Contd..9) 65
Products under Development by Companies, H2 2012 (Contd..10) 66
Products under Development by Companies, H2 2012 (Contd..11) 67
Products under Development by Companies, H2 2012 (Contd..12) 68
Products under Development by Companies, H2 2012 (Contd..13) 69
Products under Development by Companies, H2 2012 (Contd..14) 70
Products under Development by Companies, H2 2012 (Contd..15) 71
Products under Development by Companies, H2 2012 (Contd..16) 72
Products under Development by Companies, H2 2012 (Contd..17) 73
Products under Development by Companies, H2 2012 (Contd..18) 74
Products under Development by Companies, H2 2012 (Contd..19) 75
Products under Investigation by Universities/Institutes, H2 2012 76
Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 77
Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 78
Products under Investigation by Universities/Institutes, H2 2012 (Contd..3) 79
Products under Investigation by Universities/Institutes, H2 2012 (Contd..4) 80
Products under Investigation by Universities/Institutes, H2 2012 (Contd..5) 81
Products under Investigation by Universities/Institutes, H2 2012 (Contd..6) 82
Products under Investigation by Universities/Institutes, H2 2012 (Contd..7) 83
Products under Investigation by Universities/Institutes, H2 2012 (Contd..8) 84
Products under Investigation by Universities/Institutes, H2 2012 (Contd..9) 85
Products under Investigation by Universities/Institutes, H2 2012 (Contd..10) 86
Products under Investigation by Universities/Institutes, H2 2012 (Contd..11) 87
Products under Investigation by Universities/Institutes, H2 2012 (Contd..12) 88
Products under Investigation by Universities/Institutes, H2 2012 (Contd..13) 89
Products under Investigation by Universities/Institutes, H2 2012 (Contd..14) 90
Products under Investigation by Universities/Institutes, H2 2012 (Contd..15) 91
Products under Investigation by Universities/Institutes, H2 2012 (Contd..16) 92
Products under Investigation by Universities/Institutes, H2 2012 (Contd..17) 93
Products under Investigation by Universities/Institutes, H2 2012 (Contd..18) 94
Products under Investigation by Universities/Institutes, H2 2012 (Contd..19) 95
Products under Investigation by Universities/Institutes, H2 2012 (Contd..20) 96
Products under Investigation by Universities/Institutes, H2 2012 (Contd..21) 97
Bristol-Myers Squibb Company, H2 2012 98
Johnson & Johnson, H2 2012 99
Boehringer Ingelheim GmbH, H2 2012 100
Celsion Corporation, H2 2012 101
Abbott Laboratories, H2 2012 102
Amgen Inc., H2 2012 103
Sanofi-Aventis, H2 2012 104
Adherex Technologies Inc., H2 2012 105
AstraZeneca PLC, H2 2012 106
Eli Lilly and Company, H2 2012 107
Viralytics Ltd., H2 2012 108
GlaxoSmithKline plc, H2 2012 109
Bioniche Life Sciences, Inc., H2 2012 110
Genentech, Inc., H2 2012 111
Inovio Biomedical Corporation, H2 2012 112
Bavarian Nordic A/S, H2 2012 113
Isis Pharmaceuticals, Inc., H2 2012 114
Merck & Co., Inc., H2 2012 115
AbGenomics International, Inc., H2 2012 116
Oxford BioMedica plc, H2 2012 117
Generex Biotechnology Corporation, H2 2012 118
Takeda Pharmaceutical Company Limited, H2 2012 119
Plexxikon Inc., H2 2012 120
Light Sciences Oncology, Inc., H2 2012 121
Amorfix Life Sciences Ltd., H2 2012 122
Ipsen S.A., H2 2012 123
Panacea Pharmaceuticals, Inc., H2 2012 124
Bio-Path Holdings, Inc., H2 2012 125
BioSante Pharmaceuticals, Inc., H2 2012 126
ZIOPHARM Oncology, Inc., H2 2012 127
Millennium Pharmaceuticals, Inc., H2 2012 128
Novartis AG, H2 2012 129
Aphios Corporation, H2 2012 130
Astellas Pharma Inc., H2 2012 131
BioMarin Pharmaceutical Inc., H2 2012 132
Cephalon, Inc., H2 2012 133
Genta Incorporated, H2 2012 134
GTx, Inc., H2 2012 135
Nippon Shinyaku Co., Ltd., H2 2012 136
Orion Corporation, H2 2012 137
Pfizer Inc., H2 2012 138
Teva Pharmaceutical Industries Limited, H2 2012 139
Progenics Pharmaceuticals, Inc., H2 2012 140
Santaris Pharma A/S, H2 2012 141
Exelixis, Inc., H2 2012 142
Aduro BioTech, H2 2012 143
Menarini Group, H2 2012 144
Alfacell Corporation, H2 2012 145
Celgene Corporation, H2 2012 146
Bayer AG, H2 2012 147
MannKind Corporation, H2 2012 148
Merck KGaA, H2 2012 149
Advaxis, Inc., H2 2012 150
Alchemia Limited, H2 2012 151
Addex Pharmaceuticals, H2 2012 152
Genesis Research and Development Corporation Ltd., H2 2012 153
GW Pharmaceuticals plc, H2 2012 154
Hollis-Eden Pharmaceuticals, Inc., H2 2012 155
Celldex Therapeutics, Inc., H2 2012 156
Anavex Life Sciences Corp., H2 2012 157
Cougar Biotechnology, Inc., H2 2012 158
ValiRx Plc, H2 2012 159
Active Biotech AB, H2 2012 160
AEterna Zentaris Inc., H2 2012 161
Antisense Therapeutics Limited, H2 2012 162
Bionomics Limited, H2 2012 163
Molecular Insight Pharmaceuticals, Inc., H2 2012 164
Northwest Biotherapeutics, Inc., H2 2012 165
Novelos Therapeutics, Inc., H2 2012 166
Nymox Pharmaceutical Corporation, H2 2012 167
Cleveland BioLabs, Inc., H2 2012 168
Oncolytics Biotech Inc., H2 2012 169
Oncothyreon Inc, H2 2012 170
Compugen Ltd., H2 2012 171
Osta Biotechnologies Inc., H2 2012 172
Peregrine Pharmaceuticals, Inc., H2 2012 173
Medivation, Inc., H2 2012 174
La Jolla Pharmaceutical Company, H2 2012 175
Jazz Pharmaceuticals, Inc., H2 2012 176
ADVENTRX Pharmaceuticals, H2 2012 177
Telik, Inc., H2 2012 178
Soligenix, Inc., H2 2012 179
Poniard Pharmaceuticals, Inc., H2 2012 180
Regeneron Pharmaceuticals, Inc., H2 2012 181
Champions Biotechnology, Inc., H2 2012 182
Oncogenex Pharmaceuticals, Inc., H2 2012 183
ProMetic Life Sciences Inc., H2 2012 184
Progen Pharmaceuticals Limited, H2 2012 185
Green Cross Corporation, H2 2012 186
Innocell Corporation, H2 2012 187
Quest PharmaTech Inc., H2 2012 188
Samaritan Pharmaceuticals, Inc., H2 2012 189
Threshold Pharmaceuticals, Inc., H2 2012 190
Synta Pharmaceuticals Corp., H2 2012 191
Sareum Holdings plc, H2 2012 192
Oasmia Pharmaceutical AB, H2 2012 193
e-Therapeutics plc, H2 2012 194
RXi Pharmaceuticals Corporation, H2 2012 195
Hybrigenics S.A., H2 2012 196
Rexahn Pharmaceuticals, Inc., H2 2012 197
Merrion Pharmaceuticals Plc, H2 2012 198
Emiliem, Inc., H2 2012 199

List of Figures
Number of Products under Development for Prostate Cancer, H2 2012 24
Products under Development for Prostate Cancer – Comparative Analysis, H2 2012 25
Products under Development by Companies, H2 2012 26
Products under Investigation by Universities/Institutes, H2 2012 42
Late Stage Products, H2 2012 52
Mid Clinical Stage Products, H2 2012 53
Early Clinical Stage Products, H2 2012 54
Discovery and Pre-Clinical Stage Products, H2 2012 55
Assessment by Monotherapy Products, H2 2012 290
Assessment by Combination Products, H2 2012 291
Assessment by Route of Administration, H2 2012 292
Assessment by Stage and Route of Administration, H2 2012 293
Assessment by Molecule Type, H2 2012 294
Assessment by Stage and Molecule Type, H2 2012 295

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos